Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Fintel reports that on February 27, 2025, Stifel initiated coverage of COMPASS Pathways plc - Depositary Receipt () (NasdaqGS:CMPS) with a Buy recommendation. As of February 19, 2025, the average ...

Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for ...

The average one-year price target for COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) has been revised to $19.84 / share. This is an increase of 12.63% from the prior estimate of $17.62 ...

Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the COMPASS ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...